Veracyte Wins Medicare Coverage for Bladder Cancer MRD Test
Event summary
- Veracyte's TrueMRD Monitoring Test secured Medicare coverage for muscle-invasive bladder cancer recurrence monitoring.
- Commercial launch begins June 1, 2026, marking Veracyte's first molecular residual disease (MRD) offering.
- Test detected recurrence median of 131 days earlier than imaging in pivotal PAGER study.
- TrueMRD is the only commercially available whole-genome MRD test currently on market.
The big picture
This Medicare coverage represents a significant validation of molecular residual disease testing in oncology, positioning Veracyte at the forefront of a growing trend toward precision monitoring. The approval comes as bladder cancer treatment paradigms shift toward more personalized approaches and bladder-sparing strategies. With approximately 25% of new bladder cancer cases being muscle-invasive and high recurrence rates, this test addresses a substantial unmet need in surveillance.
What we're watching
- Market Expansion
- Whether Veracyte can successfully expand its TrueMRD platform across additional cancer types beyond bladder cancer.
- Clinical Adoption
- The pace at which clinicians will incorporate this earlier detection capability into treatment protocols for MIBC patients.
- Competitive Positioning
- How Veracyte's whole-genome approach differentiates it from competitors developing more targeted MRD solutions.
Related topics